Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
FYI - 08 May 2024
Vacancies List
Therapeutics
Medicinal Chemist
Scientist/Senior Scientist (Immunology)
Diagnostics
No current vacancies
---------------------------------
https://avacta.com/careers/scientist-senior-scientist-immunology/
https://avacta.com/careers/medicinal-chemist/
https://view.officeapps.live.com/op/view.aspx?src=https%3A%2F%2Favacta.com%2Fwp-content%2Fuploads%2F2024%2F05%2FScientist-Snr-Immunology-April-2024-CAREERS-PAGE.docx&wdOrigin=BROWSELINK
https://avacta.com/wp-content/uploads/2024/05/Avacta-Medicinal-Chemist-May-2024-FINAL28.pdf
They’ll never talk above integrating the Affimer into Dx again, now AS has left.
Gmcc..gotchya on that...but it says next generation of treatments and I was thinking more on the lines of an Affimer based product...
I'VE been considering the taxation of options and wonder if the final decision by AS to leave was taken on 9th April and a combination of valuations at the moment and £M severance package may actually mean that everyone, including AS are reasonably happy with the situation.
Oops " separate "
"Avacta Diagnostics expected to be overall EBITDA positive in second half of 2024 and cash generative 2025"
Anyway good or bad decision , it happened ,still on Avacta Balance sheet , so worthwhile making it work .
Perhaps Avacta might sell Coris & LD as seperate entities ?
Energy,
Please don’t use a generic document to set a deadline here. Whilst that guide may be correct for AS’s leaving it also may not be.
The reality is that ‘leaving’ for senior people is usually to some extent a process of negotiation whatever the circumstances. Even when the decision comes heavily from one side or the other there will be a settlement agreement that will govern how the departure occurs including with certainty that AS will not be able to speak about it.
The Board will of course have to act in the best interests of shareholders in reaching a settlement with AS
I’ve still never seen anything to validate why Launch was ever bought 🤭😢
@ Bella6532 : AMR Global issue not just the UK : Avacta well placed with Coris /LD :
"Anti-Microbial Resistance concern pushed Coris BioConcept to develop a range of assays (RESIST) for rapid detection of antibiotic resistance mechanisms. Aside of this range, another innovative approach for 3GC detection was recently launched with a front line test: BL-RED.
This R&D expertise is ideally suited for “on demand” production of innovative solutions in a rapidly changing world that calls for cutting edge biotechnology to take us forward into a healthy future.
All Coris BioConcept’s products fulfil the CE marking requirements with an ISO 13485 certification and they are used in over 60 countries all over the world.
Coris BioConcept is now part of Avacta Group."
----------------
"Coris BioConcept is a leading expert in the field of rapid diagnostics kits. Based in Belgium and established in 1996, the company develops, produces and markets diagnostic kits, mainly for the detection of human infectious pathogens (bacteria, virus and parasites), and for the detection of antibiotic resistance markers.
These rapid tests are based on the immunochromatographic (also known as lateral flow), the isothermal LAMP and the electrochemical technologies and are extensively used in microbiology laboratories worldwide.
Coris BioConcept is currently involved in multiple collaborative international projects (including Belgian and/or European grants) for the development of new rapid diagnostic assays, with focus on antimicrobial resistance and neglected tropical and emerging diseases.
This R&D expertise is ideally suited for the “on-demand” development or production of innovative solutions in a rapidly changing world that calls for cutting edge biotechnology to take us forward into a healthy future.
All Coris BioConcept’s products fulfill the CE marking requirements and the company is also certified ISO 13485.
--------------
'incentivise industry to develop the next generation of treatments'
OK so Launch is a Distributor of a new product but I wonder if Coris and Avacta DX can benefit.
Good timing
"Launch Diagnostics LimitedLaunch Diagnostics Limited
1,659 followers1,659 followers
1h • Edited • 1 hour ago
On the 4th April 2024 the Medicines and Healthcare products Regulatory Agency (MHRA) approved the combined antibiotic cefepime/enmetazobactam (brand name Exblifep) to treat adult patients with complicated infections of the urinary tract and certain types of pneumonia.
Enmetazobactam blocks the action of beta-lactamases, allowing cefepime to act against bacteria that would otherwise be resistant.
We are pleased to announce the addition of cefepime-enmetazobactam to the Liofilchem MTS (MIC Test Strip) range.
Launch Diagnostics is the exclusive distributor of Liofilchem's portfolio in the UK.
For all your AMR testing solutions, head over to our website: www.launchdiagnostics.com, or contact enquiries@launchdiagnostics.com
#microbiology #antimicrobialstewardship #antimicrobialresistance
#AMR #NHS #antibiotics #antimicrobials #patientcare"
If we're going for the conjecture sweepstakes on AS's dismissal, then here we go:
It is fairly routine for start ups to have their board removed shortly after they IPO or large investors get on board when the company is moving out of the start up phase, as they're often seen as blockers. They may be very good at coming up with the initial idea and getting that off the ground, but they often don't have the skills required to scale or commercialise. Not only that they can be emotionally attached to their baby, or still in ideas mode, losing focus on pushing through their original good idea.
I also think that AS has been led by the nose by Turner Pope et al. When they called me up they seemed to want to stress the special relationship they've had with AS over the years. Yes, special in that they can squeeze his nuts from time to time and make a killing.
All in all, the last raise, the distraction and diversion of the dx venture, which would have made even truss proud, were the last straw, and shareholders had enough. After all 19 years is long enough for a start up to emerge from the incubator. Ironically that last dilution might have been some desperate last attempt to alter the register in his favour to save his bacon.
There is nothing yet to tell us that the 2w arm will take another 6 months from now, but agree an update on this would help restore sentiment.
The only statement that I can find about AS's role at Avacta is in his new position as 'Chair' at the start-up Sparta Biodiscovery where it is stated about him at https://spartabiodiscovery.com/about/
- 'Is well known [ie AS] in the UK public markets and well respected and trusted executive with many years’ experience of investor relations in the UK, Europe and US. Has also successfully delivered multiple follow-on fundraisings for the Avacta Group. '
I wonder how many LTHs would actually agree with that assessment of him?
There isn't an option at Companies House to list an Ex Director as 'sacked'
Yes that's what's needed.
Consistent tumour responses in the two week arm without excessive side effects.
If it's as good as Dox and fewer/minimal side effects then the Share Price should react very well.
Even if it's not quite as good as Standard Dox but can be given for longer or in frailer patients it'll have a large roll and then Avacta can move on to equipping Pre|Cision with more powerful warheads.
Yet to confirm the move on from the 1st Cohort of the 2 week arm however so a little longer to go.
3-6 months minimum?
The 3rd patient in the 1st Cohort was dosed 3 months after the 1st!
Getting there slowly, very slowly.
I was under the impression that he had already exercised his options.
Energy
Thanks for clarifying that. I was wondering if there was any deadline
Agree with you Goldie, but on "To those who are invested in Avacta, remember why you invested in the first place. Was it because of the science, management, or the fact that you could be investing in a company that could save millions of lives. Either way, it’s your decision", people should not invest just because they want a good outcome. If that's the only reason then they should give to an appropriate charity and let that charity invest in new therapies, palliative care or whatever.
Resigned before he was pushed by the NEDs and a painful vote at the AGM.
Hi Rambo, thanks for your thoughts.
I am not sure I agree with it all though.
I don't see any circumstantial proof to suggest he wanted AVCT to be under the radar. Although we have lamented the PR the fact we had Science days, several interviews, exhibition presentations, moving offices to become higher profile and very good data reported in the RNS's over the last 18 months or so, suggests to me that AVCT were in fact desperately trying to gather visibility.
I think the constant unpredicted delay in finishing (for whatever reason), various stages of the trial is the main reason why funding then became front and centre. (I think it was the "unexpected surprise" of having to gear up again after the 4th cohort that was pivotal as it added over a year on top of already slipping timelines.)
Can't argue with point 2&3! (but I think it was an inevitable consequence of the above)
I don't think the loan was any sort of master stroke to supress the SP. (The "we are overvalued to our peers" remark came way after that as the consequences of the delays and thus needing more funding, became crystal clear.)
Point 5: Well, that to me is the cause of all the reasons why the SP has collapsed to value it is now.
Point 6: I don't know, you may well be correct but the thing that makes me think it might not be, is that we are about to get 2WD first update, which really should be very good in both confirming how well it works and that shorter intervals between doses is more effective, so double good news, possibly the best news in AVCT history. To be able to produce that info fairly soon makes his departure right now seem a bit odd to me.
But hey ho, it is what it is.
Companies House register says he resigned. Don't know whether that is 100% believable - is 'Sacked' an option?
A.Smith left the company on 30th April.
Has until 29th July to exercise his options, or did he leave on bad terms and has lost the lot.
If a good leaver, the recipient will keep the number of options already vested, and any remaining options will be cancelled. They'll then need to exercise these options into shares within 90 days. Any options not exercised within this timeframe will be cancelled. If a bad leaver, they will lose everything.
https://www.vestd.com/help/what-if-an-employee-leaves#
Probably a bit of a biased view as the AI bot draws heavily, almost exclusively or totally, on Avacta source material! That is a consequence of Avacta having put nothing out in the peer review universe and of no one else writing independently about the application of Affimers in cancer therapeutics!
Https://www.gov.uk/government/news/new-five-year-plan-to-combat-antimicrobial-resistance
https://www.grandviewresearch.com/industry-analysis/antibiotic-resistance-market
--------------------------
antimicrobial-resistance is a global problem -Opportunity for Coris/LD as they offer AMR detection products -
---- "The Group continues its focus on consolidating the Diagnostics Division post the Launch and Coris acquisitions. After the period end Avacta announced that it is exploring strategic options for the division in a manner which maximises shareholder value "
Anyway David Wilson Avacta Chief Commercial Officer | Driving Global IVD likes this
-----------------------
Department of Health and Social CareDepartment of Health and Social Care
262,695 followers262,695 followers
1h • 1 hour ago
Follow
Today we have launched a new plan to tackle antimicrobial resistance (AMR). This national action plan commits the UK to:
🔵 reduce use of antimicrobials
🔵 strengthen surveillance of drug resistant infections before they emerge
🔵 incentivise industry to develop the next generation of treatments
See our plan on Confronting Antimicrobial Resistance: https://lnkd.in/e9Xj6NxM
hashtag#AMR hashtag#AntimicrobialResistance
UK Research and Innovation, Department for Science, Innovation and Technology, UK Health Security Agency, Department for Environment, Food and Rural Affairs, Cabinet Office"
Rambo, good summary of Alan's approach, why would he change it when it's funding his lifestyle. I disagree that right now they should look too far beyond ava6k.
They have a lovely poster, brochures available, for affimers calling out why they're superior. It's achieved nothing. They could produce the same for precision, now rebranded for a comparison against ADCs, showing how great the platform is. They need a commercial product out there proving it. Switching the pipeline to compete with ADCs isn't cheap, they're spending a lot on R&D. Personally I'd rather see them do that once they're self sustaining rather than diluting.